Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared a post on X:
“Hallmarks of cancer – what’s new beyond the original 6
- Evading immune destruction is now a core acquired capability, reflecting multi-layered TME immunosuppression and T-cell exhaustion biology.
- Deregulating cellular metabolism was added as a hallmark capability (beyond “Warburg”) to capture diverse metabolic rewiring that supports growth and survival.
- Unlocking phenotypic plasticity is the newest hallmark (introduced 2022): epigenetic flexibility enabling state switching, heterogeneity, and adaptive resistance.
- These “new” hallmarks sit within an expanded framework that also emphasizes hallmark-enabling characteristics, hallmark-conveying TME cells, and systemic interactions.
- Original 6 (reminder): sustaining proliferative signaling; inactivating growth suppressors; resisting programmed cell death; establishing replicative immortality; inducing/accessing vasculature; activating invasion and metastasis.”
Title: Hallmarks of cancer – Then and now, and beyond
Author: Douglas Hanahan
Other articles featuring Jean-Charles Soria.